<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37047548</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>31</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Advances in the Pathogenesis and Treatment of Systemic Lupus Erythematosus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">6578</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24076578</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is a genetically predisposed, female-predominant disease, characterized by multiple organ damage, that in its most severe forms can be life-threatening. The pathogenesis of SLE is complex and involves cells of both innate and adaptive immunity. The distinguishing feature of SLE is the production of autoantibodies, with the formation of immune complexes that precipitate at the vascular level, causing organ damage. Although progress in understanding the pathogenesis of SLE has been slower than in other rheumatic diseases, new knowledge has recently led to the development of effective targeted therapies, that hold out hope for personalized therapy. However, the new drugs available to date are still an adjunct to conventional therapy, which is known to be toxic in the short and long term. The purpose of this review is to summarize recent advances in understanding the pathogenesis of the disease and discuss the results obtained from the use of new targeted drugs, with a look at future therapies that may be used in the absence of the current standard of care or may even cure this serious systemic autoimmune disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Accapezzato</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-0983-3610</Identifier><AffiliationInfo><Affiliation>Division of Clinical Immunology, Department of Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caccavale</LastName><ForeName>Rosalba</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Clinical Immunology, Department of Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paroli</LastName><ForeName>Maria Pia</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0002-4395-4774</Identifier><AffiliationInfo><Affiliation>Eye Clinic, Department of Sense Organs, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gioia</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-3559-2571</Identifier><AffiliationInfo><Affiliation>Division of Clinical Immunology, Department of Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Bich Lien</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Division of Clinical Immunology, Department of Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spadea</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Post Graduate School of Public Health, University of Siena, 53100 Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paroli</LastName><ForeName>Marino</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7919-9128</Identifier><AffiliationInfo><Affiliation>Division of Clinical Immunology, Department of Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000936">Antigen-Antibody Complex</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056704" MajorTopicYN="Y">Adaptive Immunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000936" MajorTopicYN="N">Antigen-Antibody Complex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B-cells</Keyword><Keyword MajorTopicYN="N">T-cells</Keyword><Keyword MajorTopicYN="N">cell-based therapy</Keyword><Keyword MajorTopicYN="N">plasmacytoid cells</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">type-I interferon</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>13</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37047548</ArticleId><ArticleId IdType="pmc">PMC10095030</ArticleId><ArticleId IdType="doi">10.3390/ijms24076578</ArticleId><ArticleId IdType="pii">ijms24076578</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fava A., Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J. Autoimmun. 2019;96:1&#x2013;13. doi: 10.1016/j.jaut.2018.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.11.001</ArticleId><ArticleId IdType="pmc">PMC6310637</ArticleId><ArticleId IdType="pubmed">30448290</ArticleId></ArticleIdList></Reference><Reference><Citation>Justiz Vaillant A.A., Goyal A., Varacallo M. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2022. Systemic Lupus Erythematosus.</Citation><ArticleIdList><ArticleId IdType="pubmed">30571026</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrat F.J., Crow M.K., Ivashkiv L.B. Interferon target-gene expression and epigenomic signatures in health and disease. Nat. Immunol. 2019;20:1574&#x2013;1583. doi: 10.1038/s41590-019-0466-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-019-0466-2</ArticleId><ArticleId IdType="pmc">PMC7024546</ArticleId><ArticleId IdType="pubmed">31745335</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A., Kostopoulou M., Alunno A., Aringer M., Bajema I., Boletis J.N., Cervera R., Doria A., Gordon C., Govoni M., et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann. Rheum. Dis. 2019;78:736&#x2013;745. doi: 10.1136/annrheumdis-2019-215089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A., Tziolos N., Bertsias G., Boumpas D.T. Update omicronn the diagnosis and management of systemic lupus erythematosus. Ann. Rheum. Dis. 2021;80:14&#x2013;25. doi: 10.1136/annrheumdis-2020-218272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218272</ArticleId><ArticleId IdType="pubmed">33051219</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees F., Doherty M., Grainge M.J., Lanyon P., Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: A systematic review of epidemiological studies. Rheumatology. 2017;56:1945&#x2013;1961. doi: 10.1093/rheumatology/kex260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kex260</ArticleId><ArticleId IdType="pubmed">28968809</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewold T.B. Advances in lupus genetics. Curr. Opin. Rheumatol. 2015;27:440&#x2013;447. doi: 10.1097/BOR.0000000000000205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000205</ArticleId><ArticleId IdType="pmc">PMC4540605</ArticleId><ArticleId IdType="pubmed">26218512</ArticleId></ArticleIdList></Reference><Reference><Citation>Salgado-Galicia N.A., Hernandez-Dono S., Ruiz-Gomez D., Jakez-Ocampo J., Zuniga J., Vargas-Alarcon G., Acuna V., Hernandez M.T., Marquez-Garcia J.E., Garcia-Lechuga M., et al. The role of socioeconomic status in the susceptibility to develop systemic lupus erythematosus in Mexican patients. Clin. Rheumatol. 2020;39:2151&#x2013;2161. doi: 10.1007/s10067-020-04928-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-04928-5</ArticleId><ArticleId IdType="pubmed">32008155</ArticleId></ArticleIdList></Reference><Reference><Citation>Danchenko N., Satia J.A., Anthony M.S. Epidemiology of systemic lupus erythematosus: A comparison of worldwide disease burden. Lupus. 2006;15:308&#x2013;318. doi: 10.1191/0961203306lu2305xx.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203306lu2305xx</ArticleId><ArticleId IdType="pubmed">16761508</ArticleId></ArticleIdList></Reference><Reference><Citation>Stojan G., Petri M. Epidemiology of systemic lupus erythematosus: An update. Curr. Opin. Rheumatol. 2018;30:144&#x2013;150. doi: 10.1097/BOR.0000000000000480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000480</ArticleId><ArticleId IdType="pmc">PMC6026543</ArticleId><ArticleId IdType="pubmed">29251660</ArticleId></ArticleIdList></Reference><Reference><Citation>Ocampo-Piraquive V., Nieto-Aristizabal I., Canas C.A., Tobon G.J. Mortality in systemic lupus erythematosus: Causes, predictors and interventions. Expert Rev. Clin. Immunol. 2018;14:1043&#x2013;1053. doi: 10.1080/1744666X.2018.1538789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2018.1538789</ArticleId><ArticleId IdType="pubmed">30338717</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.H., Choi S.J., Ji J.D., Song G.G. Overall and cause-specific mortality in systemic lupus erythematosus: An updated meta-analysis. Lupus. 2016;25:727&#x2013;734. doi: 10.1177/0961203315627202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315627202</ArticleId><ArticleId IdType="pubmed">26811368</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauderon A., Roux-Lombard P., Spoerl D. Antinuclear Antibodies With a Homogeneous and Speckled Immunofluorescence Pattern Are Associated With Lack of Cancer While Those With a Nucleolar Pattern With the Presence of Cancer. Front. Med. 2020;7:165. doi: 10.3389/fmed.2020.00165.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00165</ArticleId><ArticleId IdType="pmc">PMC7204906</ArticleId><ArticleId IdType="pubmed">32426359</ArticleId></ArticleIdList></Reference><Reference><Citation>Applbaum E., Lichtbroun A. Novel Sjogren&#x2019;s autoantibodies found in fibromyalgia patients with sicca and/or xerostomia. Autoimmun. Rev. 2019;18:199&#x2013;202. doi: 10.1016/j.autrev.2018.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2018.09.004</ArticleId><ArticleId IdType="pubmed">30572137</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence J.M., 3rd, Moore T.L., Osborn T.G., Nesher G., Madson K.L., Kinsella M.B. Autoantibody studies in juvenile rheumatoid arthritis. Semin. Arthritis Rheum. 1993;22:265&#x2013;274. doi: 10.1016/0049-0172(93)80074-P.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0049-0172(93)80074-P</ArticleId><ArticleId IdType="pubmed">8484133</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisetsky D.S., Lipsky P.E. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat. Rev. Rheumatol. 2020;16:565&#x2013;579. doi: 10.1038/s41584-020-0480-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0480-7</ArticleId><ArticleId IdType="pmc">PMC8456518</ArticleId><ArticleId IdType="pubmed">32884126</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M.A., van Vollenhoven R.F., Buyon J., Levy R.A., Navarra S.V., Cervera R., Zhong Z.J., Freimuth W.W., Bliss, Groups B.-S. Baseline predictors of systemic lupus erythematosus flares: Data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum. 2013;65:2143&#x2013;2153. doi: 10.1002/art.37995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.37995</ArticleId><ArticleId IdType="pubmed">23754628</ArticleId></ArticleIdList></Reference><Reference><Citation>Negoro N., Kanayama Y., Takeda T., Amatsu K., Koda S., Inoue Y., Kim T., Okamura M., Inoue T. Clinical significance of U1-RNP immune complexes in mixed connective tissue disease and systemic lupus erythematosus. Rheumatol. Int. 1987;7:7&#x2013;11. doi: 10.1007/BF00267336.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00267336</ArticleId><ArticleId IdType="pubmed">2954202</ArticleId></ArticleIdList></Reference><Reference><Citation>Novak G.V., Marques M., Balbi V., Gormezano N.W., Kozu K., Sakamoto A.P., Pereira R.M., Terreri M.T., Magalhaes C.S., Guariento A., et al. Anti-RO/SSA and anti-La/SSB antibodies: Association with mild lupus manifestations in 645 childhood-onset systemic lupus erythematosus. Autoimmun. Rev. 2017;16:132&#x2013;135. doi: 10.1016/j.autrev.2016.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2016.12.004</ArticleId><ArticleId IdType="pubmed">27988434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez G.A., Canti V., Del Rosso S., Erra R., Moiola L., Magnoni M., Bozzolo E.P., Manfredi A.A., Rovere-Querini P. Diagnostic performance of aPS/PT antibodies in neuropsychiatric lupus and cardiovascular complications of systemic lupus erythematosus. Autoimmunity. 2020;53:21&#x2013;27. doi: 10.1080/08916934.2019.1696778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916934.2019.1696778</ArticleId><ArticleId IdType="pubmed">31782311</ArticleId></ArticleIdList></Reference><Reference><Citation>Unlu O., Zuily S., Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur. J. Rheumatol. 2016;3:75&#x2013;84. doi: 10.5152/eurjrheum.2015.0085.</Citation><ArticleIdList><ArticleId IdType="doi">10.5152/eurjrheum.2015.0085</ArticleId><ArticleId IdType="pmc">PMC5042235</ArticleId><ArticleId IdType="pubmed">27708976</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M., Costenbader K., Daikh D., Brinks R., Mosca M., Ramsey-Goldman R., Smolen J.S., Wofsy D., Boumpas D.T., Kamen D.L., et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann. Rheum. Dis. 2019;78:1151&#x2013;1159. doi: 10.1136/annrheumdis-2018-214819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214819</ArticleId><ArticleId IdType="pubmed">31383717</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikdashi J., Nived O. Measuring disease activity in adults with systemic lupus erythematosus: The challenges of administrative burden and responsiveness to patient concerns in clinical research. Arthritis Res. Ther. 2015;17:183. doi: 10.1186/s13075-015-0702-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-015-0702-6</ArticleId><ArticleId IdType="pmc">PMC4507322</ArticleId><ArticleId IdType="pubmed">26189728</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D.D., Ibanez D., Urowitz M.B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 2002;29:288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg D.A., Rahman A., Allen E., Farewell V., Akil M., Bruce I.N., D&#x2019;Cruz D., Griffiths B., Khamashta M., Maddison P., et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group&#x2019;s disease activity index for patients with systemic lupus erythematosus. Rheumatology. 2005;44:902&#x2013;906. doi: 10.1093/rheumatology/keh624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keh624</ArticleId><ArticleId IdType="pubmed">15814577</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D., Ginzler E., Goldsmith C., Fortin P., Liang M., Urowitz M., Bacon P., Bombardieri S., Hanly J., Hay E., et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363&#x2013;369. doi: 10.1002/art.1780390303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780390303</ArticleId><ArticleId IdType="pubmed">8607884</ArticleId></ArticleIdList></Reference><Reference><Citation>Luijten K.M., Tekstra J., Bijlsma J.W., Bijl M. The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. Autoimmun. Rev. 2012;11:326&#x2013;329. doi: 10.1016/j.autrev.2011.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2011.06.011</ArticleId><ArticleId IdType="pubmed">21958603</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson R. Distinct B cell receptor functions are determined by phosphorylation. PLoS Biol. 2006;4:e231. doi: 10.1371/journal.pbio.0040231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0040231</ArticleId><ArticleId IdType="pmc">PMC1470464</ArticleId><ArticleId IdType="pubmed">20076604</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemazee D. Mechanisms of central tolerance for B cells. Nat. Rev. Immunol. 2017;17:281&#x2013;294. doi: 10.1038/nri.2017.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2017.19</ArticleId><ArticleId IdType="pmc">PMC5623591</ArticleId><ArticleId IdType="pubmed">28368006</ArticleId></ArticleIdList></Reference><Reference><Citation>Zikherman J., Parameswaran R., Weiss A. Endogenous antigen tunes the responsiveness of naive B cells but not T cells. Nature. 2012;489:160&#x2013;164. doi: 10.1038/nature11311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11311</ArticleId><ArticleId IdType="pmc">PMC3438375</ArticleId><ArticleId IdType="pubmed">22902503</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett D.L., Langley D.B., Schofield P., Hermes J.R., Chan T.D., Jackson J., Bourne K., Reed J.H., Patterson K., Porebski B.T., et al. Germinal center antibody mutation trajectories are determined by rapid self/foreign discrimination. Science. 2018;360:223&#x2013;226. doi: 10.1126/science.aao3859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aao3859</ArticleId><ArticleId IdType="pmc">PMC5922412</ArticleId><ArticleId IdType="pubmed">29650674</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackay F., Schneider P. Cracking the BAFF code. Nat. Rev. Immunol. 2009;9:491&#x2013;502. doi: 10.1038/nri2572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2572</ArticleId><ArticleId IdType="pubmed">19521398</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson S.W., Davidson A. BAFF inhibition in SLE-Is tolerance restored? Immunol. Rev. 2019;292:102&#x2013;119. doi: 10.1111/imr.12810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12810</ArticleId><ArticleId IdType="pmc">PMC6935406</ArticleId><ArticleId IdType="pubmed">31562657</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006;25:417&#x2013;428. doi: 10.1016/j.immuni.2006.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.07.013</ArticleId><ArticleId IdType="pubmed">16973389</ArticleId></ArticleIdList></Reference><Reference><Citation>Berland R., Fernandez L., Kari E., Han J.H., Lomakin I., Akira S., Wortis H.H., Kearney J.F., Ucci A.A., Imanishi-Kari T. Toll-like receptor 7-dependent loss of B cell tolerance in pathogenic autoantibody knockin mice. Immunity. 2006;25:429&#x2013;440. doi: 10.1016/j.immuni.2006.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.07.014</ArticleId><ArticleId IdType="pubmed">16973388</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen S.R., Kashgarian M., Alexopoulou L., Flavell R.A., Akira S., Shlomchik M.J. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 2005;202:321&#x2013;331. doi: 10.1084/jem.20050338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20050338</ArticleId><ArticleId IdType="pmc">PMC2212997</ArticleId><ArticleId IdType="pubmed">16027240</ArticleId></ArticleIdList></Reference><Reference><Citation>Lartigue A., Courville P., Auquit I., Francois A., Arnoult C., Tron F., Gilbert D., Musette P. Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus. J. Immunol. 2006;177:1349&#x2013;1354. doi: 10.4049/jimmunol.177.2.1349.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.2.1349</ArticleId><ArticleId IdType="pubmed">16818796</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutt S.L., Hodgkin P.D., Tarlinton D.M., Corcoran L.M. The generation of antibody-secreting plasma cells. Nat. Rev. Immunol. 2015;15:160&#x2013;171. doi: 10.1038/nri3795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3795</ArticleId><ArticleId IdType="pubmed">25698678</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinuesa C.G., Sanz I., Cook M.C. Dysregulation of germinal centres in autoimmune disease. Nat. Rev. Immunol. 2009;9:845&#x2013;857. doi: 10.1038/nri2637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2637</ArticleId><ArticleId IdType="pubmed">19935804</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan O., Shlomchik M.J. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J. Immunol. 1998;160:51&#x2013;59. doi: 10.4049/jimmunol.160.1.51.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.160.1.51</ArticleId><ArticleId IdType="pubmed">9551955</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan O.T., Hannum L.G., Haberman A.M., Madaio M.P., Shlomchik M.J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 1999;189:1639&#x2013;1648. doi: 10.1084/jem.189.10.1639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.189.10.1639</ArticleId><ArticleId IdType="pmc">PMC2193634</ArticleId><ArticleId IdType="pubmed">10330443</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffler D., Schur P.H., Kunkel H.G. Immunological studies concerning the nephritis of systemic lupus erythematosus. J. Exp. Med. 1967;126:607&#x2013;624. doi: 10.1084/jem.126.4.607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.126.4.607</ArticleId><ArticleId IdType="pmc">PMC2138388</ArticleId><ArticleId IdType="pubmed">4168098</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrenstein M.R., Katz D.R., Griffiths M.H., Papadaki L., Winkler T.H., Kalden J.R., Isenberg D.A. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int. 1995;48:705&#x2013;711. doi: 10.1038/ki.1995.341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1995.341</ArticleId><ArticleId IdType="pubmed">7474655</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannik M., Merrill C.E., Stamps L.D., Wener M.H. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J. Rheumatol. 2003;30:1495&#x2013;1504.</Citation><ArticleIdList><ArticleId IdType="pubmed">12858447</ArticleId></ArticleIdList></Reference><Reference><Citation>Izmirly P.M., Rivera T.L., Buyon J.P. Neonatal lupus syndromes. Rheum. Dis. Clin. N. Am. 2007;33:267&#x2013;285. doi: 10.1016/j.rdc.2007.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2007.02.005</ArticleId><ArticleId IdType="pubmed">17499707</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah D., Kiran R., Wanchu A., Bhatnagar A. Oxidative stress in systemic lupus erythematosus: Relationship to Th1 cytokine and disease activity. Immunol. Lett. 2010;129:7&#x2013;12. doi: 10.1016/j.imlet.2010.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2010.01.005</ArticleId><ArticleId IdType="pubmed">20105444</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugimoto K., Morimoto S., Kaneko H., Nozawa K., Tokano Y., Takasaki Y., Hashimoto H. Decreased IL-4 producing CD4+ T cells in patients with active systemic lupus erythematosus-relation to IL-12R expression. Autoimmunity. 2002;35:381&#x2013;387. doi: 10.1080/0891693021000008535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0891693021000008535</ArticleId><ArticleId IdType="pubmed">12568118</ArticleId></ArticleIdList></Reference><Reference><Citation>Paroli M., Caccavale R., Fiorillo M.T., Spadea L., Gumina S., Candela V., Paroli M.P. The Double Game Played by Th17 Cells in Infection: Host Defense and Immunopathology. Pathogens. 2022;11:1547. doi: 10.3390/pathogens11121547.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11121547</ArticleId><ArticleId IdType="pmc">PMC9781511</ArticleId><ArticleId IdType="pubmed">36558881</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez P., Rodriguez-Carrio J., Caminal-Montero L., Mozo L., Suarez A. A pathogenic IFNalpha, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients. Sci. Rep. 2016;6:20651. doi: 10.1038/srep20651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep20651</ArticleId><ArticleId IdType="pmc">PMC4742957</ArticleId><ArticleId IdType="pubmed">26847824</ArticleId></ArticleIdList></Reference><Reference><Citation>Zickert A., Amoudruz P., Sundstrom Y., Ronnelid J., Malmstrom V., Gunnarsson I. IL-17 and IL-23 in lupus nephritis&#x2014;association to histopathology and response to treatment. BMC Immunol. 2015;16:7. doi: 10.1186/s12865-015-0070-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-015-0070-7</ArticleId><ArticleId IdType="pmc">PMC4326189</ArticleId><ArticleId IdType="pubmed">25887118</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonelli M., Savitskaya A., von Dalwigk K., Steiner C.W., Aletaha D., Smolen J.S., Scheinecker C. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE) Int. Immunol. 2008;20:861&#x2013;868. doi: 10.1093/intimm/dxn044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxn044</ArticleId><ArticleId IdType="pubmed">18469329</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander T., Sattler A., Templin L., Kohler S., Gross C., Meisel A., Sawitzki B., Burmester G.R., Arnold R., Radbruch A., et al. Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus. Ann. Rheum. Dis. 2013;72:1549&#x2013;1558. doi: 10.1136/annrheumdis-2012-202216.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202216</ArticleId><ArticleId IdType="pubmed">23264341</ArticleId></ArticleIdList></Reference><Reference><Citation>La Cava A. Tregs in SLE: An Update. Curr. Rheumatol. Rep. 2018;20:6. doi: 10.1007/s11926-018-0714-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-018-0714-8</ArticleId><ArticleId IdType="pubmed">29464438</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P.M., Tsokos G.C. T Cell Abnormalities in the Pathogenesis of Systemic Lupus Erythematosus: An Update. Curr. Rheumatol. Rep. 2021;23:12. doi: 10.1007/s11926-020-00978-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-020-00978-5</ArticleId><ArticleId IdType="pmc">PMC8601587</ArticleId><ArticleId IdType="pubmed">33512577</ArticleId></ArticleIdList></Reference><Reference><Citation>Liarski V.M., Kaverina N., Chang A., Brandt D., Yanez D., Talasnik L., Carlesso G., Herbst R., Utset T.O., Labno C., et al. Cell distance mapping identifies functional T follicular helper cells in inflamed human renal tissue. Sci. Transl. Med. 2014;6:230ra246. doi: 10.1126/scitranslmed.3008146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3008146</ArticleId><ArticleId IdType="pmc">PMC4129446</ArticleId><ArticleId IdType="pubmed">24695686</ArticleId></ArticleIdList></Reference><Reference><Citation>Comte D., Karampetsou M.P., Yoshida N., Kis-Toth K., Kyttaris V.C., Tsokos G.C. Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017;69:1035&#x2013;1044. doi: 10.1002/art.40038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40038</ArticleId><ArticleId IdType="pmc">PMC5406259</ArticleId><ArticleId IdType="pubmed">28076903</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinney E.F., Lee J.C., Jayne D.R., Lyons P.A., Smith K.G. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature. 2015;523:612&#x2013;616. doi: 10.1038/nature14468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14468</ArticleId><ArticleId IdType="pmc">PMC4623162</ArticleId><ArticleId IdType="pubmed">26123020</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuyama E., Suarez-Fueyo A., Bradley S.J., Mizui M., Marin A.V., Mulki L., Krishfield S., Malavasi F., Yoon J., Sui S.J.H., et al. The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 T Cell Function and Identifies Patients with SLE Prone to Infections. Cell Rep. 2020;30:112&#x2013;123.e114. doi: 10.1016/j.celrep.2019.12.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.12.014</ArticleId><ArticleId IdType="pmc">PMC7577012</ArticleId><ArticleId IdType="pubmed">31914379</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Kang N., Zhang X., Dong X., Wei W., Cui L., Ba D., He W. Generation of human regulatory gammadelta T cells by TCRgammadelta stimulation in the presence of TGF-beta and their involvement in the pathogenesis of systemic lupus erythematosus. J. Immunol. 2011;186:6693&#x2013;6700. doi: 10.4049/jimmunol.1002776.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1002776</ArticleId><ArticleId IdType="pubmed">21562160</ArticleId></ArticleIdList></Reference><Reference><Citation>Robak E., Niewiadomska H., Robak T., Bartkowiak J., Blonski J.Z., Wozniacka A., Pomorski L., Sysa-Jedrezejowska A. Lymphocyctes Tgammadelta in clinically normal skin and peripheral blood of patients with systemic lupus erythematosus and their correlation with disease activity. Mediat. Inflamm. 2001;10:179&#x2013;189. doi: 10.1080/09629350124724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09629350124724</ArticleId><ArticleId IdType="pmc">PMC1781712</ArticleId><ArticleId IdType="pubmed">11577994</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandt L., Hedberg H. Impaired phagocytosis by peripheral blood granulocytes in systemic lupus erythematosus. Scand. J. Haematol. 1969;6:348&#x2013;353. doi: 10.1111/j.1600-0609.1969.tb02420.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0609.1969.tb02420.x</ArticleId><ArticleId IdType="pubmed">4188539</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly S., Roake W., Brown S., Young P., Naik H., Wordsworth P., Isenberg D.A., Reid K.B., Eggleton P. Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus. Arthritis Rheum. 2006;54:1543&#x2013;1556. doi: 10.1002/art.21783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21783</ArticleId><ArticleId IdType="pubmed">16645988</ArticleId></ArticleIdList></Reference><Reference><Citation>Lood C., Blanco L.P., Purmalek M.M., Carmona-Rivera C., De Ravin S.S., Smith C.K., Malech H.L., Ledbetter J.A., Elkon K.B., Kaplan M.J. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat. Med. 2016;22:146&#x2013;153. doi: 10.1038/nm.4027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4027</ArticleId><ArticleId IdType="pmc">PMC4742415</ArticleId><ArticleId IdType="pubmed">26779811</ArticleId></ArticleIdList></Reference><Reference><Citation>Hom G., Graham R.R., Modrek B., Taylor K.E., Ortmann W., Garnier S., Lee A.T., Chung S.A., Ferreira R.C., Pant P.V., et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N. Engl. J. Med. 2008;358:900&#x2013;909. doi: 10.1056/NEJMoa0707865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0707865</ArticleId><ArticleId IdType="pubmed">18204098</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson L.M., Johansson A.C., Gullstrand B., Jonsen A., Saevarsdottir S., Ronnblom L., Leonard D., Wettero J., Sjowall C., Svenungsson E., et al. A single nucleotide polymorphism in the NCF1 gene leading to reduced oxidative burst is associated with systemic lupus erythematosus. Ann. Rheum. Dis. 2017;76:1607&#x2013;1613. doi: 10.1136/annrheumdis-2017-211287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211287</ArticleId><ArticleId IdType="pubmed">28606963</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob C.O., Eisenstein M., Dinauer M.C., Ming W., Liu Q., John S., Quismorio F.P., Jr., Reiff A., Myones B.L., Kaufman K.M., et al. Lupus-associated causal mutation in neutrophil cytosolic factor 2 (NCF2) brings unique insights to the structure and function of NADPH oxidase. Proc. Natl. Acad. Sci. USA. 2012;109:E59&#x2013;E67. doi: 10.1073/pnas.1113251108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1113251108</ArticleId><ArticleId IdType="pmc">PMC3258621</ArticleId><ArticleId IdType="pubmed">22203994</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindau D., Mussard J., Rabsteyn A., Ribon M., Kotter I., Igney A., Adema G.J., Boissier M.C., Rammensee H.G., Decker P. TLR9 independent interferon alpha production by neutrophils on NETosis in response to circulating chromatin, a key lupus autoantigen. Ann. Rheum. Dis. 2014;73:2199&#x2013;2207. doi: 10.1136/annrheumdis-2012-203041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-203041</ArticleId><ArticleId IdType="pubmed">24013727</ArticleId></ArticleIdList></Reference><Reference><Citation>Palanichamy A., Bauer J.W., Yalavarthi S., Meednu N., Barnard J., Owen T., Cistrone C., Bird A., Rabinovich A., Nevarez S., et al. Neutrophil-mediated IFN activation in the bone marrow alters B cell development in human and murine systemic lupus erythematosus. J. Immunol. 2014;192:906&#x2013;918. doi: 10.4049/jimmunol.1302112.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1302112</ArticleId><ArticleId IdType="pmc">PMC3907774</ArticleId><ArticleId IdType="pubmed">24379124</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman S., Sagar D., Hanna R.N., Lightfoot Y.L., Mistry P., Smith C.K., Manna Z., Hasni S., Siegel R.M., Sanjuan M.A., et al. Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus. Ann. Rheum. Dis. 2019;78:957&#x2013;966. doi: 10.1136/annrheumdis-2018-214620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214620</ArticleId><ArticleId IdType="pmc">PMC6585283</ArticleId><ArticleId IdType="pubmed">31040119</ArticleId></ArticleIdList></Reference><Reference><Citation>Midgley A., Beresford M.W. Increased expression of low density granulocytes in juvenile-onset systemic lupus erythematosus patients correlates with disease activity. Lupus. 2016;25:407&#x2013;411. doi: 10.1177/0961203315608959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203315608959</ArticleId><ArticleId IdType="pubmed">26453665</ArticleId></ArticleIdList></Reference><Reference><Citation>Denny M.F., Yalavarthi S., Zhao W., Thacker S.G., Anderson M., Sandy A.R., McCune W.J., Kaplan M.J. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J. Immunol. 2010;184:3284&#x2013;3297. doi: 10.4049/jimmunol.0902199.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0902199</ArticleId><ArticleId IdType="pmc">PMC2929645</ArticleId><ArticleId IdType="pubmed">20164424</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeltz S., Amini P., Anders H.J., Andrade F., Bilyy R., Chatfield S., Cichon I., Clancy D.M., Desai J., Dumych T., et al. To NET or not to NET:current opinions and state of the science regarding the formation of neutrophil extracellular traps. Cell Death Differ. 2019;26:395&#x2013;408. doi: 10.1038/s41418-018-0261-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-018-0261-x</ArticleId><ArticleId IdType="pmc">PMC6370810</ArticleId><ArticleId IdType="pubmed">30622307</ArticleId></ArticleIdList></Reference><Reference><Citation>Apel F., Zychlinsky A., Kenny E.F. The role of neutrophil extracellular traps in rheumatic diseases. Nat. Rev. Rheumatol. 2018;14:467&#x2013;475. doi: 10.1038/s41584-018-0039-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-018-0039-z</ArticleId><ArticleId IdType="pubmed">29930301</ArticleId></ArticleIdList></Reference><Reference><Citation>Odqvist L., Jevnikar Z., Riise R., Oberg L., Rhedin M., Leonard D., Yrlid L., Jackson S., Mattsson J., Nanda S., et al. Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. Ann. Rheum. Dis. 2019;78:1363&#x2013;1370. doi: 10.1136/annrheumdis-2019-215434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215434</ArticleId><ArticleId IdType="pmc">PMC6788882</ArticleId><ArticleId IdType="pubmed">31300459</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang H.H., Dwivedi N., Nicholas A.P., Ho I.C. The W620 Polymorphism in PTPN22 Disrupts Its Interaction With Peptidylarginine Deiminase Type 4 and Enhances Citrullination and NETosis. Arthritis Rheumatol. 2015;67:2323&#x2013;2334. doi: 10.1002/art.39215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39215</ArticleId><ArticleId IdType="pubmed">26019128</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Matta B., Song S., Nelson V., Diggins K., Simpfendorfer K.R., Gregersen P.K., Linsley P., Barnes B.J. IRF5 genetic risk variants drive myeloid-specific IRF5 hyperactivation and presymptomatic SLE. JCI Insight. 2020;5:e124020. doi: 10.1172/jci.insight.124020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.124020</ArticleId><ArticleId IdType="pmc">PMC7098722</ArticleId><ArticleId IdType="pubmed">31877114</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel R.R., Nakabo S., Dizon B.L.P., Urban A., Waldman M., Howard L., Darnell D., Buhaya M., Carmona-Rivera C., Hasni S., et al. Lupus-like autoimmunity and increased interferon response in patients with STAT3-deficient hyper-IgE syndrome. J. Allergy Clin. Immunol. 2021;147:746&#x2013;749.e9. doi: 10.1016/j.jaci.2020.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.07.024</ArticleId><ArticleId IdType="pmc">PMC7862417</ArticleId><ArticleId IdType="pubmed">32768442</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlenberg J.M., Carmona-Rivera C., Smith C.K., Kaplan M.J. Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J. Immunol. 2013;190:1217&#x2013;1226. doi: 10.4049/jimmunol.1202388.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1202388</ArticleId><ArticleId IdType="pmc">PMC3552129</ArticleId><ArticleId IdType="pubmed">23267025</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisirak V., Ganguly D., Lewis K.L., Couillault C., Tanaka L., Bolland S., D&#x2019;Agati V., Elkon K.B., Reizis B. Genetic evidence for the role of plasmacytoid dendritic cells in systemic lupus erythematosus. J. Exp. Med. 2014;211:1969&#x2013;1976. doi: 10.1084/jem.20132522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20132522</ArticleId><ArticleId IdType="pmc">PMC4172218</ArticleId><ArticleId IdType="pubmed">25180061</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiore N., Castellano G., Blasi A., Capobianco C., Loverre A., Montinaro V., Netti S., Torres D., Manno C., Grandaliano G., et al. Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis. Mol. Immunol. 2008;45:259&#x2013;265. doi: 10.1016/j.molimm.2007.04.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2007.04.029</ArticleId><ArticleId IdType="pubmed">17570528</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakata K., Nakayamada S., Miyazaki Y., Kubo S., Ishii A., Nakano K., Tanaka Y. Up-Regulation of TLR7-Mediated IFN-alpha Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus. Front. Immunol. 2018;9:1957. doi: 10.3389/fimmu.2018.01957.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01957</ArticleId><ArticleId IdType="pmc">PMC6121190</ArticleId><ArticleId IdType="pubmed">30210502</ArticleId></ArticleIdList></Reference><Reference><Citation>Bave U., Magnusson M., Eloranta M.L., Perers A., Alm G.V., Ronnblom L. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J. Immunol. 2003;171:3296&#x2013;3302. doi: 10.4049/jimmunol.171.6.3296.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.171.6.3296</ArticleId><ArticleId IdType="pubmed">12960360</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Romo G.S., Caielli S., Vega B., Connolly J., Allantaz F., Xu Z., Punaro M., Baisch J., Guiducci C., Coffman R.L., et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 2011;3:73ra20. doi: 10.1126/scitranslmed.3001201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3001201</ArticleId><ArticleId IdType="pmc">PMC3143837</ArticleId><ArticleId IdType="pubmed">21389264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hjorton K., The DISSECT consortium. Hagberg N., Israelsson E., Jinton L., Berggren O., Sandling J.K., Th&#xf6;rn K., Mo J., Eloranta M.-L., et al. Cytokine production by activated plasmacytoid dendritic cells and natural killer cells is suppressed by an IRAK4 inhibitor. Arthritis Res. Ther. 2018;20:238. doi: 10.1186/s13075-018-1702-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-018-1702-0</ArticleId><ArticleId IdType="pmc">PMC6235225</ArticleId><ArticleId IdType="pubmed">30355354</ArticleId></ArticleIdList></Reference><Reference><Citation>Corzo C.A., Varfolomeev E., Setiadi A.F., Francis R., Klabunde S., Senger K., Sujatha-Bhaskar S., Drobnick J., Do S., Suto E., et al. The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells. Sci. Signal. 2020;13:eaaz1053. doi: 10.1126/scisignal.aaz1053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.aaz1053</ArticleId><ArticleId IdType="pubmed">32487715</ArticleId></ArticleIdList></Reference><Reference><Citation>Swiecki M., Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat. Rev. Immunol. 2015;15:471&#x2013;485. doi: 10.1038/nri3865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3865</ArticleId><ArticleId IdType="pmc">PMC4808588</ArticleId><ArticleId IdType="pubmed">26160613</ArticleId></ArticleIdList></Reference><Reference><Citation>Jego G., Palucka A.K., Blanck J.P., Chalouni C., Pascual V., Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003;19:225&#x2013;234. doi: 10.1016/S1074-7613(03)00208-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(03)00208-5</ArticleId><ArticleId IdType="pubmed">12932356</ArticleId></ArticleIdList></Reference><Reference><Citation>Soni C., Perez O.A., Voss W.N., Pucella J.N., Serpas L., Mehl J., Ching K.L., Goike J., Georgiou G., Ippolito G.C., et al. Plasmacytoid Dendritic Cells and Type I Interferon Promote Extrafollicular B Cell Responses to Extracellular Self-DNA. Immunity. 2020;52:1022&#x2013;1038.e1027. doi: 10.1016/j.immuni.2020.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.04.015</ArticleId><ArticleId IdType="pmc">PMC7306002</ArticleId><ArticleId IdType="pubmed">32454024</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement M., Charles N., Escoubet B., Guedj K., Chauveheid M.P., Caligiuri G., Nicoletti A., Papo T., Sacre K. CD4+CXCR3+ T cells and plasmacytoid dendritic cells drive accelerated atherosclerosis associated with systemic lupus erythematosus. J. Autoimmun. 2015;63:59&#x2013;67. doi: 10.1016/j.jaut.2015.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2015.07.001</ArticleId><ArticleId IdType="pubmed">26183767</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito T., Yang M., Wang Y.H., Lande R., Gregorio J., Perng O.A., Qin X.F., Liu Y.J., Gilliet M. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J. Exp. Med. 2007;204:105&#x2013;115. doi: 10.1084/jem.20061660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20061660</ArticleId><ArticleId IdType="pmc">PMC2118437</ArticleId><ArticleId IdType="pubmed">17200410</ArticleId></ArticleIdList></Reference><Reference><Citation>Jahrsdorfer B., Vollmer A., Blackwell S.E., Maier J., Sontheimer K., Beyer T., Mandel B., Lunov O., Tron K., Nienhaus G.U., et al. Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood. 2010;115:1156&#x2013;1165. doi: 10.1182/blood-2009-07-235382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-07-235382</ArticleId><ArticleId IdType="pmc">PMC2920226</ArticleId><ArticleId IdType="pubmed">19965634</ArticleId></ArticleIdList></Reference><Reference><Citation>Moseman E.A., Liang X., Dawson A.J., Panoskaltsis-Mortari A., Krieg A.M., Liu Y.J., Blazar B.R., Chen W. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J. Immunol. 2004;173:4433&#x2013;4442. doi: 10.4049/jimmunol.173.7.4433.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.173.7.4433</ArticleId><ArticleId IdType="pubmed">15383574</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon M., Blair P.A., Isenberg D.A., Mauri C. A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus. Immunity. 2016;44:683&#x2013;697. doi: 10.1016/j.immuni.2016.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2016.02.012</ArticleId><ArticleId IdType="pmc">PMC4803914</ArticleId><ArticleId IdType="pubmed">26968426</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams J.P., Leslie A.G., Lutter R., Walker J.E. Structure at 2.8 A resolution of F1-ATPase from bovine heart mitochondria. Nature. 1994;370:621&#x2013;628. doi: 10.1038/370621a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/370621a0</ArticleId><ArticleId IdType="pubmed">8065448</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam K., Moinuddin, Jabeen S. Immunogenicity of mitochondrial DNA modified by hydroxyl radical. Cell. Immunol. 2007;247:12&#x2013;17. doi: 10.1016/j.cellimm.2007.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2007.06.007</ArticleId><ArticleId IdType="pubmed">17716639</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L., Duvvuri B., Grigull J., Jamnik R., Wither J.E., Wu G.E. Experimental evidence that mutated-self peptides derived from mitochondrial DNA somatic mutations have the potential to trigger autoimmunity. Hum. Immunol. 2014;75:873&#x2013;879. doi: 10.1016/j.humimm.2014.06.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2014.06.012</ArticleId><ArticleId IdType="pubmed">24979674</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Lopez L., Nieves-Plaza M., Castro Mdel R., Font Y.M., Torres-Ramos C.A., Vila L.M., Ayala-Pena S. Mitochondrial DNA damage is associated with damage accrual and disease duration in patients with systemic lupus erythematosus. Lupus. 2014;23:1133&#x2013;1141. doi: 10.1177/0961203314537697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314537697</ArticleId><ArticleId IdType="pmc">PMC4156531</ArticleId><ArticleId IdType="pubmed">24899636</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Raoof M., Chen Y., Sumi Y., Sursal T., Junger W., Brohi K., Itagaki K., Hauser C.J. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:104&#x2013;107. doi: 10.1038/nature08780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08780</ArticleId><ArticleId IdType="pmc">PMC2843437</ArticleId><ArticleId IdType="pubmed">20203610</ArticleId></ArticleIdList></Reference><Reference><Citation>Vyshkina T., Sylvester A., Sadiq S., Bonilla E., Canter J.A., Perl A., Kalman B. Association of common mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus. Clin. Immunol. 2008;129:31&#x2013;35. doi: 10.1016/j.clim.2008.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2008.07.011</ArticleId><ArticleId IdType="pmc">PMC2567049</ArticleId><ArticleId IdType="pubmed">18708297</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsen A., Yu X., Truedsson L., Nived O., Sturfelt G., Ibrahim S., Bengtsson A. Mitochondrial DNA polymorphisms are associated with susceptibility and phenotype of systemic lupus erythematosus. Lupus. 2009;18:309&#x2013;312. doi: 10.1177/0961203308097477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203308097477</ArticleId><ArticleId IdType="pubmed">19276298</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y., Wang L., Zhu M., Yang M., Zhong K., Du Q., Zhang H., Gui M. Association of mtDNA M/N haplogroups with systemic lupus erythematosus: A case-control study of Han Chinese women. Sci. Rep. 2015;5:10817. doi: 10.1038/srep10817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep10817</ArticleId><ArticleId IdType="pmc">PMC4454022</ArticleId><ArticleId IdType="pubmed">26039690</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu X., Wester-Rosenlof L., Gimsa U., Holzhueter S.A., Marques A., Jonas L., Hagenow K., Kunz M., Nizze H., Tiedge M., et al. The mtDNA nt7778 G/T polymorphism affects autoimmune diseases and reproductive performance in the mouse. Hum. Mol. Genet. 2009;18:4689&#x2013;4698. doi: 10.1093/hmg/ddp432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp432</ArticleId><ArticleId IdType="pubmed">19759059</ArticleId></ArticleIdList></Reference><Reference><Citation>Caielli S., Athale S., Domic B., Murat E., Chandra M., Banchereau R., Baisch J., Phelps K., Clayton S., Gong M., et al. Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus. J. Exp. Med. 2016;213:697&#x2013;713. doi: 10.1084/jem.20151876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20151876</ArticleId><ArticleId IdType="pmc">PMC4854735</ArticleId><ArticleId IdType="pubmed">27091841</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker Y., Marcoux G., Allaeys I., Julien A.S., Loignon R.C., Benk-Fortin H., Rollet-Labelle E., Rauch J., Fortin P.R., Boilard E. Autoantibodies in Systemic Lupus Erythematosus Target Mitochondrial RNA. Front. Immunol. 2019;10:1026. doi: 10.3389/fimmu.2019.01026.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01026</ArticleId><ArticleId IdType="pmc">PMC6524553</ArticleId><ArticleId IdType="pubmed">31134086</ArticleId></ArticleIdList></Reference><Reference><Citation>Sisirak V., Sally B., D&#x2019;Agati V., Martinez-Ortiz W., Ozcakar Z.B., David J., Rashidfarrokhi A., Yeste A., Panea C., Chida A.S., et al. Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity. Cell. 2016;166:88&#x2013;101. doi: 10.1016/j.cell.2016.05.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.05.034</ArticleId><ArticleId IdType="pmc">PMC5030815</ArticleId><ArticleId IdType="pubmed">27293190</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Mayouf S.M., Sunker A., Abdwani R., Abrawi S.A., Almurshedi F., Alhashmi N., Al Sonbul A., Sewairi W., Qari A., Abdallah E., et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat. Genet. 2011;43:1186&#x2013;1188. doi: 10.1038/ng.975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.975</ArticleId><ArticleId IdType="pubmed">22019780</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartl J., Serpas L., Wang Y., Rashidfarrokhi A., Perez O.A., Sally B., Sisirak V., Soni C., Khodadadi-Jamayran A., Tsirigos A., et al. Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. J. Exp. Med. 2021;218:e20201138. doi: 10.1084/jem.20201138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201138</ArticleId><ArticleId IdType="pmc">PMC8020718</ArticleId><ArticleId IdType="pubmed">33783474</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawane K., Fukuyama H., Kondoh G., Takeda J., Ohsawa Y., Uchiyama Y., Nagata S. Requirement of DNase II for definitive erythropoiesis in the mouse fetal liver. Science. 2001;292:1546&#x2013;1549. doi: 10.1126/science.292.5521.1546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.292.5521.1546</ArticleId><ArticleId IdType="pubmed">11375492</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida H., Okabe Y., Kawane K., Fukuyama H., Nagata S. Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA. Nat. Immunol. 2005;6:49&#x2013;56. doi: 10.1038/ni1146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1146</ArticleId><ArticleId IdType="pubmed">15568025</ArticleId></ArticleIdList></Reference><Reference><Citation>Grieves J.L., Fye J.M., Harvey S., Grayson J.M., Hollis T., Perrino F.W. Exonuclease TREX1 degrades double-stranded DNA to prevent spontaneous lupus-like inflammatory disease. Proc. Natl. Acad. Sci. USA. 2015;112:5117&#x2013;5122. doi: 10.1073/pnas.1423804112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1423804112</ArticleId><ArticleId IdType="pmc">PMC4413332</ArticleId><ArticleId IdType="pubmed">25848017</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow Y.J., Hayward B.E., Parmar R., Robins P., Leitch A., Ali M., Black D.N., van Bokhoven H., Brunner H.G., Hamel B.C., et al. Mutations in the gene encoding the 3&#x2032;-5&#x2032; DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat. Genet. 2006;38:917&#x2013;920. doi: 10.1038/ng1845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1845</ArticleId><ArticleId IdType="pubmed">16845398</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinde R., Hezaveh K., Halaby M.J., Kloetgen A., Chakravarthy A., da Silva Medina T., Deol R., Manion K.P., Baglaenko Y., Eldh M., et al. Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans. Nat. Immunol. 2018;19:571&#x2013;582. doi: 10.1038/s41590-018-0107-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-018-0107-1</ArticleId><ArticleId IdType="pmc">PMC5976527</ArticleId><ArticleId IdType="pubmed">29760532</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravishankar B., Liu H., Shinde R., Chandler P., Baban B., Tanaka M., Munn D.H., Mellor A.L., Karlsson M.C., McGaha T.L. Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase. Proc. Natl. Acad. Sci. USA. 2012;109:3909&#x2013;3914. doi: 10.1073/pnas.1117736109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1117736109</ArticleId><ArticleId IdType="pmc">PMC3309765</ArticleId><ArticleId IdType="pubmed">22355111</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravishankar B., Liu H., Shinde R., Chaudhary K., Xiao W., Bradley J., Koritzinsky M., Madaio M.P., McGaha T.L. The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity. Proc. Natl. Acad. Sci. USA. 2015;112:10774&#x2013;10779. doi: 10.1073/pnas.1504276112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1504276112</ArticleId><ArticleId IdType="pmc">PMC4553766</ArticleId><ArticleId IdType="pubmed">26261340</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaux D.L., Flavell R.A. Apoptosis genes and autoimmunity. Curr. Opin. Immunol. 2000;12:719&#x2013;724. doi: 10.1016/S0952-7915(00)00168-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0952-7915(00)00168-0</ArticleId><ArticleId IdType="pubmed">11102778</ArticleId></ArticleIdList></Reference><Reference><Citation>Henson P.M., Hume D.A. Apoptotic cell removal in development and tissue homeostasis. Trends Immunol. 2006;27:244&#x2013;250. doi: 10.1016/j.it.2006.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2006.03.005</ArticleId><ArticleId IdType="pubmed">16584921</ArticleId></ArticleIdList></Reference><Reference><Citation>Devitt A., Parker K.G., Ogden C.A., Oldreive C., Clay M.F., Melville L.A., Bellamy C.O., Lacy-Hulbert A., Gangloff S.C., Goyert S.M., et al. Persistence of apoptotic cells without autoimmune disease or inflammation in CD14-/- mice. J. Cell Biol. 2004;167:1161&#x2013;1170. doi: 10.1083/jcb.200410057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200410057</ArticleId><ArticleId IdType="pmc">PMC2172617</ArticleId><ArticleId IdType="pubmed">15611337</ArticleId></ArticleIdList></Reference><Reference><Citation>Lande R., Ganguly D., Facchinetti V., Frasca L., Conrad C., Gregorio J., Meller S., Chamilos G., Sebasigari R., Riccieri V., et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 2011;3:73ra19. doi: 10.1126/scitranslmed.3001180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3001180</ArticleId><ArticleId IdType="pmc">PMC3399524</ArticleId><ArticleId IdType="pubmed">21389263</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow M.K., Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res. Ther. 2003;5:279&#x2013;287. doi: 10.1186/ar1015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar1015</ArticleId><ArticleId IdType="pmc">PMC333417</ArticleId><ArticleId IdType="pubmed">14680503</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivashkiv L.B. IFNgamma: Signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat. Rev. Immunol. 2018;18:545&#x2013;558. doi: 10.1038/s41577-018-0029-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-018-0029-z</ArticleId><ArticleId IdType="pmc">PMC6340644</ArticleId><ArticleId IdType="pubmed">29921905</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S., Baldridge M.T. Interferon-Lambda: A Potent Regulator of Intestinal Viral Infections. Front. Immunol. 2017;8:749. doi: 10.3389/fimmu.2017.00749.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00749</ArticleId><ArticleId IdType="pmc">PMC5491552</ArticleId><ArticleId IdType="pubmed">28713375</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 2014;14:36&#x2013;49. doi: 10.1038/nri3581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3581</ArticleId><ArticleId IdType="pmc">PMC4084561</ArticleId><ArticleId IdType="pubmed">24362405</ArticleId></ArticleIdList></Reference><Reference><Citation>Chyuan I.T., Tzeng H.T., Chen J.Y. Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus. Cells. 2019;8:963. doi: 10.3390/cells8090963.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells8090963</ArticleId><ArticleId IdType="pmc">PMC6769759</ArticleId><ArticleId IdType="pubmed">31450787</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y.J. IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 2005;23:275&#x2013;306. doi: 10.1146/annurev.immunol.23.021704.115633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.23.021704.115633</ArticleId><ArticleId IdType="pubmed">15771572</ArticleId></ArticleIdList></Reference><Reference><Citation>Petro T.M. IFN Regulatory Factor 3 in Health and Disease. J. Immunol. 2020;205:1981&#x2013;1989. doi: 10.4049/jimmunol.2000462.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2000462</ArticleId><ArticleId IdType="pubmed">33020188</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., Antonenko S., Liu Y.J. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999;284:1835&#x2013;1837. doi: 10.1126/science.284.5421.1835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.284.5421.1835</ArticleId><ArticleId IdType="pubmed">10364556</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoggins J.W. Interferon-Stimulated Genes: What Do They All Do? Annu. Rev. Virol. 2019;6:567&#x2013;584. doi: 10.1146/annurev-virology-092818-015756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-virology-092818-015756</ArticleId><ArticleId IdType="pubmed">31283436</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark G.R., Darnell J.E., Jr. The JAK-STAT pathway at twenty. Immunity. 2012;36:503&#x2013;514. doi: 10.1016/j.immuni.2012.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2012.03.013</ArticleId><ArticleId IdType="pmc">PMC3909993</ArticleId><ArticleId IdType="pubmed">22520844</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg A.D., Baron S., Talal N. The pathogenesis of autoimmunity in New Zealand mice, I. Induction of antinucleic acid antibodies by polyinosinic-polycytidylic acid. Proc. Natl. Acad. Sci. USA. 1969;63:1102&#x2013;1107. doi: 10.1073/pnas.63.4.1102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.63.4.1102</ArticleId><ArticleId IdType="pmc">PMC223434</ArticleId><ArticleId IdType="pubmed">5307809</ArticleId></ArticleIdList></Reference><Reference><Citation>Okanoue T., Sakamoto S., Itoh Y., Minami M., Yasui K., Sakamoto M., Nishioji K., Katagishi T., Nakagawa Y., Tada H., et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J. Hepatol. 1996;25:283&#x2013;291. doi: 10.1016/S0168-8278(96)80113-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-8278(96)80113-9</ArticleId><ArticleId IdType="pubmed">8895006</ArticleId></ArticleIdList></Reference><Reference><Citation>Gota C., Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity. 2003;36:511&#x2013;518. doi: 10.1080/08916930310001605873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930310001605873</ArticleId><ArticleId IdType="pubmed">14984028</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewold T.B. Interferon alpha-induced lupus: Proof of principle. J. Clin. Rheumatol. 2008;14:131&#x2013;132. doi: 10.1097/RHU.0b013e318177627d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RHU.0b013e318177627d</ArticleId><ArticleId IdType="pmc">PMC2743115</ArticleId><ArticleId IdType="pubmed">18525429</ArticleId></ArticleIdList></Reference><Reference><Citation>Niewold T.B., Swedler W.I. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin. Rheumatol. 2005;24:178&#x2013;181. doi: 10.1007/s10067-004-1024-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-004-1024-2</ArticleId><ArticleId IdType="pubmed">15565395</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson L.E., Widman D., Dikman S.H., Gorevic P.D. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin. Arthritis Rheum. 2002;32:163&#x2013;173. doi: 10.1053/sarh.2002.37277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/sarh.2002.37277</ArticleId><ArticleId IdType="pubmed">12528081</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham R.R., Kozyrev S.V., Baechler E.C., Reddy M.V., Plenge R.M., Bauer J.W., Ortmann W.A., Koeuth T., Gonzalez Escribano M.F., the Argentine and Spanish Collaborative Groups et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat. Genet. 2006;38:550&#x2013;555. doi: 10.1038/ng1782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1782</ArticleId><ArticleId IdType="pubmed">16642019</ArticleId></ArticleIdList></Reference><Reference><Citation>International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN) Harley J.B., Alarcon-Riquelme M.E., Criswell L.A., Jacob C.O., Kimberly R.P., Moser K.L., Tsao B.P., Vyse T.J., Langefeld C.D., et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 2008;40:204&#x2013;210. doi: 10.1038/ng.81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.81</ArticleId><ArticleId IdType="pmc">PMC3712260</ArticleId><ArticleId IdType="pubmed">18204446</ArticleId></ArticleIdList></Reference><Reference><Citation>Lessard C.J., Adrianto I., Ice J.A., Wiley G.B., Kelly J.A., Glenn S.B., Adler A.J., Li H., Rasmussen A., Williams A.H., et al. Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am. J. Hum. Genet. 2012;90:648&#x2013;660. doi: 10.1016/j.ajhg.2012.02.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2012.02.023</ArticleId><ArticleId IdType="pmc">PMC3322228</ArticleId><ArticleId IdType="pubmed">22464253</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghodke-Puranik Y., Niewold T.B. Genetics of the type I interferon pathway in systemic lupus erythematosus. Int. J. Clin. Rheumtol. 2013;8:657&#x2013;669. doi: 10.2217/ijr.13.58.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/ijr.13.58</ArticleId><ArticleId IdType="pmc">PMC3885171</ArticleId><ArticleId IdType="pubmed">24416080</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven R., Askanase A.D., Bomback A.S., Bruce I.N., Carroll A., Dall&#x2019;Era M., Daniels M., Levy R.A., Schwarting A., Quasny H.A., et al. Conceptual framework for defining disease modification in systemic lupus erythematosus: A call for formal criteria. Lupus Sci. Med. 2022;9:e000634. doi: 10.1136/lupus-2021-000634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000634</ArticleId><ArticleId IdType="pmc">PMC8961173</ArticleId><ArticleId IdType="pubmed">35346982</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven R., Voskuyl A., Bertsias G., Aranow C., Aringer M., Arnaud L., Askanase A., Balazova P., Bonfa E., Bootsma H., et al. A framework for remission in SLE: Consensus findings from a large international task force on definitions of remission in SLE (DORIS) Ann. Rheum. Dis. 2017;76:554&#x2013;561. doi: 10.1136/annrheumdis-2016-209519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2016-209519</ArticleId><ArticleId IdType="pubmed">27884822</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklyn K., Lau C.S., Navarra S.V., Louthrenoo W., Lateef A., Hamijoyo L., Wahono C.S., Chen S.L., Jin O., Morton S., et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS) Ann. Rheum. Dis. 2016;75:1615&#x2013;1621. doi: 10.1136/annrheumdis-2015-207726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207726</ArticleId><ArticleId IdType="pubmed">26458737</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida-Brasil C.C., Hanly J.G., Urowitz M., Clarke A.E., Ruiz-Irastorza G., Gordon C., Ramsey-Goldman R., Petri M., Ginzler E.M., Wallace D.J., et al. Flares after hydroxychloroquine reduction or discontinuation: Results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann. Rheum. Dis. 2022;81:370&#x2013;378. doi: 10.1136/annrheumdis-2021-221295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221295</ArticleId><ArticleId IdType="pmc">PMC8862090</ArticleId><ArticleId IdType="pubmed">34911705</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinjo S.K., Bonfa E., Wojdyla D., Borba E.F., Ramirez L.A., Scherbarth H.R., Brenol J.C., Chacon-Diaz R., Neira O.J., Berbotto G.A., et al. Antimalarial treatment may have a time-dependent effect on lupus survival: Data from a multinational Latin American inception cohort. Arthritis Rheum. 2010;62:855&#x2013;862. doi: 10.1002/art.27300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27300</ArticleId><ArticleId IdType="pubmed">20131238</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G., Ramos-Casals M., Brito-Zeron P., Khamashta M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review. Ann. Rheum. Dis. 2010;69:20&#x2013;28. doi: 10.1136/ard.2008.101766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.101766</ArticleId><ArticleId IdType="pubmed">19103632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil M.F., Mak A., Leong J., Dharmadhikari B., Kow N.Y., Reategui-Sokolova C., Elera-Fitzcarrald C., Aranow C., Arnaud L., Askanase A.D., et al. Impact of glucocorticoids on the incidence of lupus-related major organ damage: A systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Sci. Med. 2021;8:e000590. doi: 10.1136/lupus-2021-000590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000590</ArticleId><ArticleId IdType="pmc">PMC8689160</ArticleId><ArticleId IdType="pubmed">34930819</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderka M.T., Lin A.E., Abuelo D.N., Mitchell A.A., Rasmussen S.A. Reviewing the evidence for mycophenolate mofetil as a new teratogen: Case report and review of the literature. Am. J. Med. Genet. A. 2009;149A:1241&#x2013;1248. doi: 10.1002/ajmg.a.32685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.a.32685</ArticleId><ArticleId IdType="pubmed">19441125</ArticleId></ArticleIdList></Reference><Reference><Citation>Houssiau F.A., Vasconcelos C., D&#x2019;Cruz D., Sebastiani G.D., Garrido E.D.R., Danieli M.G., Abramovicz D., Blockmans D., Mathieu A., Direskeneli H., et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121&#x2013;2131. doi: 10.1002/art.10461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10461</ArticleId><ArticleId IdType="pubmed">12209517</ArticleId></ArticleIdList></Reference><Reference><Citation>Emadi A., Jones R.J., Brodsky R.A. Cyclophosphamide and cancer: Golden anniversary. Nat. Rev. Clin. Oncol. 2009;6:638&#x2013;647. doi: 10.1038/nrclinonc.2009.146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrclinonc.2009.146</ArticleId><ArticleId IdType="pubmed">19786984</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorner T., Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393:2344&#x2013;2358. doi: 10.1016/S0140-6736(19)30546-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30546-X</ArticleId><ArticleId IdType="pubmed">31180031</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., Utset T.O., Gordon C., Isenberg D.A., Hsieh H.J., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222&#x2013;233. doi: 10.1002/art.27233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.27233</ArticleId><ArticleId IdType="pmc">PMC4548300</ArticleId><ArticleId IdType="pubmed">20039413</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin B.H., Furie R., Latinis K., Looney R.J., Fervenza F.C., Sanchez-Guerrero J., Maciuca R., Zhang D., Garg J.P., Brunetta P., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64:1215&#x2013;1226. doi: 10.1002/art.34359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34359</ArticleId><ArticleId IdType="pubmed">22231479</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng Y.K., Levarht E.W., Toes R.E., Huizinga T.W., van Laar J.M. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann. Rheum. Dis. 2009;68:1011&#x2013;1016. doi: 10.1136/ard.2008.092791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.092791</ArticleId><ArticleId IdType="pubmed">18647852</ArticleId></ArticleIdList></Reference><Reference><Citation>Pijpe J., Meijer J.M., Bootsma H., van der Wal J.E., Spijkervet F.K., Kallenberg C.G., Vissink A., Ihrler S. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjogren&#x2019;s syndrome. Arthritis Rheum. 2009;60:3251&#x2013;3256. doi: 10.1002/art.24903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24903</ArticleId><ArticleId IdType="pubmed">19877054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kansal R., Richardson N., Neeli I., Khawaja S., Chamberlain D., Ghani M., Ghani Q.U., Balazs L., Beranova-Giorgianni S., Giorgianni F., et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci. Transl. Med. 2019;11:eaav1648. doi: 10.1126/scitranslmed.aav1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aav1648</ArticleId><ArticleId IdType="pmc">PMC8201923</ArticleId><ArticleId IdType="pubmed">30842314</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez Mendez L.M., Cascino M.D., Garg J., Katsumoto T.R., Brakeman P., Dall&#x2019;Era M., Looney R.J., Rovin B., Dragone L., Brunetta P. Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis. Clin. J. Am. Soc. Nephrol. 2018;13:1502&#x2013;1509. doi: 10.2215/CJN.01070118.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.01070118</ArticleId><ArticleId IdType="pmc">PMC6218830</ArticleId><ArticleId IdType="pubmed">30089664</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer S., Evers M., Jansen J.H.M., Buijs J., Broek B., Reitsma S.E., Moerer P., Amini M., Kretschmer A., Ten Broeke T., et al. New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies. Br. J. Haematol. 2018;180:808&#x2013;820. doi: 10.1111/bjh.15132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.15132</ArticleId><ArticleId IdType="pubmed">29468712</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinov A.D., Wang H., Bastacky S.I., van Puijenbroek E., Schindler T., Speziale D., Perro M., Klein C., Nickerson K.M., Shlomchik M.J. The Type II Anti-CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model. Arthritis Rheumatol. 2021;73:826&#x2013;836. doi: 10.1002/art.41608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41608</ArticleId><ArticleId IdType="pmc">PMC8084886</ArticleId><ArticleId IdType="pubmed">33277983</ArticleId></ArticleIdList></Reference><Reference><Citation>Mysler E.F., Spindler A.J., Guzman R., Bijl M., Jayne D., Furie R.A., Houssiau F.A., Drappa J., Close D., Maciuca R., et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013;65:2368&#x2013;2379. doi: 10.1002/art.38037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38037</ArticleId><ArticleId IdType="pubmed">23740801</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarra S.V., Guzman R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., Li E.K., Thomas M., Kim H.Y., Leon M.G., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721&#x2013;731. doi: 10.1016/S0140-6736(10)61354-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61354-2</ArticleId><ArticleId IdType="pubmed">21296403</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R., Petri M., Zamani O., Cervera R., Wallace D.J., Tegzova D., Sanchez-Guerrero J., Schwarting A., Merrill J.T., Chatham W.W., et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918&#x2013;3930. doi: 10.1002/art.30613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30613</ArticleId><ArticleId IdType="pmc">PMC5007058</ArticleId><ArticleId IdType="pubmed">22127708</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven R.F., Petri M.A., Cervera R., Roth D.A., Ji B.N., Kleoudis C.S., Zhong Z.J., Freimuth W. Belimumab in the treatment of systemic lupus erythematosus: High disease activity predictors of response. Ann. Rheum. Dis. 2012;71:1343&#x2013;1349. doi: 10.1136/annrheumdis-2011-200937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2011-200937</ArticleId><ArticleId IdType="pmc">PMC3396451</ArticleId><ArticleId IdType="pubmed">22337213</ArticleId></ArticleIdList></Reference><Reference><Citation>Urowitz M.B., Ohsfeldt R.L., Wielage R.C., Kelton K.A., Asukai Y., Ramachandran S. Organ damage in patients treated with belimumab versus standard of care: A propensity score-matched comparative analysis. Ann. Rheum. Dis. 2019;78:372&#x2013;379. doi: 10.1136/annrheumdis-2018-214043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214043</ArticleId><ArticleId IdType="pmc">PMC6390027</ArticleId><ArticleId IdType="pubmed">30610066</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R.A., Wallace D.J., Aranow C., Fettiplace J., Wilson B., Mistry P., Roth D.A., Gordon D. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States. Arthritis Rheumatol. 2018;70:868&#x2013;877. doi: 10.1002/art.40439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40439</ArticleId><ArticleId IdType="pmc">PMC6001779</ArticleId><ArticleId IdType="pubmed">29409143</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven R.F., Navarra S.V., Levy R.A., Thomas M., Heath A., Lustine T., Adamkovic A., Fettiplace J., Wang M.L., Ji B., et al. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: A Phase III study extension. Rheumatology. 2020;59:281&#x2013;291. doi: 10.1093/rheumatology/kez279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kez279</ArticleId><ArticleId IdType="pmc">PMC7571485</ArticleId><ArticleId IdType="pubmed">31302695</ArticleId></ArticleIdList></Reference><Reference><Citation>Stohl W., Schwarting A., Okada M., Scheinberg M., Doria A., Hammer A.E., Kleoudis C., Groark J., Bass D., Fox N.L., et al. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. Arthritis Rheumatol. 2017;69:1016&#x2013;1027. doi: 10.1002/art.40049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40049</ArticleId><ArticleId IdType="pmc">PMC5434872</ArticleId><ArticleId IdType="pubmed">28118533</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner H.I., Abud-Mendoza C., Viola D.O., Calvo Penades I., Levy D., Anton J., Calderon J.E., Chasnyk V.G., Ferrandiz M.A., Keltsev V., et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: Results from a randomised, placebo-controlled trial. Ann. Rheum. Dis. 2020;79:1340&#x2013;1348. doi: 10.1136/annrheumdis-2020-217101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217101</ArticleId><ArticleId IdType="pmc">PMC7509523</ArticleId><ArticleId IdType="pubmed">32699034</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R., Rovin B.H., Houssiau F., Malvar A., Teng Y.K.O., Contreras G., Amoura Z., Yu X., Mok C.C., Santiago M.B., et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N. Engl. J. Med. 2020;383:1117&#x2013;1128. doi: 10.1056/NEJMoa2001180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId><ArticleId IdType="pubmed">32937045</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin B.H., Furie R., Teng Y.K.O., Contreras G., Malvar A., Yu X., Ji B., Green Y., Gonzalez-Rivera T., Bass D., et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022;101:403&#x2013;413. doi: 10.1016/j.kint.2021.08.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.08.027</ArticleId><ArticleId IdType="pubmed">34560137</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y., Tummala R. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: An overview from clinical trials. Mod. Rheumatol. 2021;31:1&#x2013;12. doi: 10.1080/14397595.2020.1812201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2020.1812201</ArticleId><ArticleId IdType="pubmed">32814461</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R., Khamashta M., Merrill J.T., Werth V.P., Kalunian K., Brohawn P., Illei G.G., Drappa J., Wang L., Yoo S., et al. Anifrolumab, an Anti-Interferon-alpha Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017;69:376&#x2013;386. doi: 10.1002/art.39962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39962</ArticleId><ArticleId IdType="pmc">PMC5299497</ArticleId><ArticleId IdType="pubmed">28130918</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R.A., Morand E.F., Bruce I.N., Manzi S., Kalunian K.C., Vital E.M., Ford T.L., Gupta R., Hiepe F., Santiago M. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1:e208&#x2013;e219. doi: 10.1016/S2665-9913(19)30076-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(19)30076-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand E.F., Furie R., Tanaka Y., Bruce I.N., Askanase A.D., Richez C., Bae S.C., Brohawn P.Z., Pineda L., Berglind A., et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N. Engl. J. Med. 2020;382:211&#x2013;221. doi: 10.1056/NEJMoa1912196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R., Morand E.F., Askanase A.D., Vital E.M., Merrill J.T., Kalyani R.N., Abreu G., Pineda L., Tummala R. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus. 2021;30:1254&#x2013;1263. doi: 10.1177/09612033211014267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211014267</ArticleId><ArticleId IdType="pubmed">33977796</ArticleId></ArticleIdList></Reference><Reference><Citation>Vital E.M., Merrill J.T., Morand E.F., Furie R.A., Bruce I.N., Tanaka Y., Manzi S., Kalunian K.C., Kalyani R.N., Streicher K., et al. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: Post hoc analysis of pooled data from two phase III trials. Ann. Rheum. Dis. 2022;81:951&#x2013;961. doi: 10.1136/annrheumdis-2021-221425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221425</ArticleId><ArticleId IdType="pmc">PMC9213795</ArticleId><ArticleId IdType="pubmed">35338035</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne D., Rovin B., Mysler E.F., Furie R.A., Houssiau F.A., Trasieva T., Knagenhjelm J., Schwetje E., Chia Y.L., Tummala R., et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann. Rheum. Dis. 2022;81:496&#x2013;506. doi: 10.1136/annrheumdis-2021-221478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221478</ArticleId><ArticleId IdType="pmc">PMC8921596</ArticleId><ArticleId IdType="pubmed">35144924</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo Y.A. Voclosporin: First Approval. Drugs. 2021;81:605&#x2013;610. doi: 10.1007/s40265-021-01488-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-021-01488-z</ArticleId><ArticleId IdType="pmc">PMC8010786</ArticleId><ArticleId IdType="pubmed">33788181</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin B.H., Teng Y.K.O., Ginzler E.M., Arriens C., Caster D.J., Romero-Diaz J., Gibson K., Kaplan J., Lisk L., Navarra S., et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397:2070&#x2013;2080. doi: 10.1016/S0140-6736(21)00578-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00578-X</ArticleId><ArticleId IdType="pubmed">33971155</ArticleId></ArticleIdList></Reference><Reference><Citation>Rovin B.H., Solomons N., Pendergraft W.F., 3rd, Dooley M.A., Tumlin J., Romero-Diaz J., Lysenko L., Navarra S.V., Huizinga R.B., Group A.-L.S. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019;95:219&#x2013;231. doi: 10.1016/j.kint.2018.08.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2018.08.025</ArticleId><ArticleId IdType="pubmed">30420324</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholz J.L., Crowley J.E., Tomayko M.M., Steinel N., O&#x2019;Neill P.J., Quinn W.J., 3rd, Goenka R., Miller J.P., Cho Y.H., Long V., et al. BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact. Proc. Natl. Acad. Sci. USA. 2008;105:15517&#x2013;15522. doi: 10.1073/pnas.0807841105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0807841105</ArticleId><ArticleId IdType="pmc">PMC2563088</ArticleId><ArticleId IdType="pubmed">18832171</ArticleId></ArticleIdList></Reference><Reference><Citation>Neubert K., Meister S., Moser K., Weisel F., Maseda D., Amann K., Wiethe C., Winkler T.H., Kalden J.R., Manz R.A., et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 2008;14:748&#x2013;755. doi: 10.1038/nm1763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1763</ArticleId><ArticleId IdType="pubmed">18542049</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T., Tanaka Y., Kawakami A., Saito K., Ichinose K., Fujii H., Shirota Y., Shirai T., Fujita Y., Watanabe R., et al. Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. Mod. Rheumatol. 2018;28:986&#x2013;992. doi: 10.1080/14397595.2018.1432331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2018.1432331</ArticleId><ArticleId IdType="pubmed">29363990</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladi E., Everett C., Stivala C.E., Daniels B.E., Durk M.R., Harris S.F., Huestis M.P., Purkey H.E., Staben S.T., Augustin M., et al. Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability. J. Med. Chem. 2019;62:7032&#x2013;7041. doi: 10.1021/acs.jmedchem.9b00509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.9b00509</ArticleId><ArticleId IdType="pubmed">31283222</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson K.C. Progress and Paradigms in Multiple Myeloma. Clin. Cancer Res. 2016;22:5419&#x2013;5427. doi: 10.1158/1078-0432.CCR-16-0625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-16-0625</ArticleId><ArticleId IdType="pmc">PMC5300651</ArticleId><ArticleId IdType="pubmed">28151709</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostendorf L., Burns M., Durek P., Heinz G.A., Heinrich F., Garantziotis P., Enghard P., Richter U., Biesen R., Schneider U., et al. Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. N. Engl. J. Med. 2020;383:1149&#x2013;1155. doi: 10.1056/NEJMoa2023325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2023325</ArticleId><ArticleId IdType="pubmed">32937047</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenks S.A., Cashman K.S., Zumaquero E., Marigorta U.M., Patel A.V., Wang X., Tomar D., Woodruff M.C., Simon Z., Bugrovsky R., et al. Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. Immunity. 2018;49:725&#x2013;739.e726. doi: 10.1016/j.immuni.2018.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.08.015</ArticleId><ArticleId IdType="pmc">PMC6217820</ArticleId><ArticleId IdType="pubmed">30314758</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte R.F., Labopin M., Bader P., Basak G.W., Bonini C., Chabannon C., Corbacioglu S., Dreger P., Dufour C., Gennery A.R., et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2019. Bone Marrow Transpl. 2019;54:1525&#x2013;1552. doi: 10.1038/s41409-019-0516-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41409-019-0516-2</ArticleId><ArticleId IdType="pubmed">30953028</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander T., Greco R., Snowden J.A. Hematopoietic Stem Cell Transplantation for Autoimmune Disease. Annu. Rev. Med. 2021;72:215&#x2013;228. doi: 10.1146/annurev-med-070119-115617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-070119-115617</ArticleId><ArticleId IdType="pubmed">33106103</ArticleId></ArticleIdList></Reference><Reference><Citation>Zand M.S., Vo T., Pellegrin T., Felgar R., Liesveld J.L., Ifthikharuddin J.J., Abboud C.N., Sanz I., Huggins J. Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood. 2006;107:2895&#x2013;2903. doi: 10.1182/blood-2005-06-2269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2005-06-2269</ArticleId><ArticleId IdType="pmc">PMC1895388</ArticleId><ArticleId IdType="pubmed">16368890</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander T., Arnold R., Hiepe F., Radbruch A. Resetting the immune system with immunoablation and autologous haematopoietic stem cell transplantation in autoimmune diseases. Clin. Exp. Rheumatol. 2016;34:53&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">27586805</ArticleId></ArticleIdList></Reference><Reference><Citation>Swart J.F., Delemarre E.M., van Wijk F., Boelens J.J., Kuball J., van Laar J.M., Wulffraat N.M. Haematopoietic stem cell transplantation for autoimmune diseases. Nat. Rev. Rheumatol. 2017;13:244&#x2013;256. doi: 10.1038/nrrheum.2017.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2017.7</ArticleId><ArticleId IdType="pubmed">28228650</ArticleId></ArticleIdList></Reference><Reference><Citation>Shifa I., Hazlewood G.S., Durand C., Barr S.G., Mydlarski P.R., Beck P.L., Burton J.M., Khan F.M., Jamani K., Osman M., et al. Efficacy of Allogeneic Hematopoietic Cell Transplantation for Autoimmune Diseases. Transpl. Cell. Ther. 2021;27:489.e1&#x2013;489.e9. doi: 10.1016/j.jtct.2021.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtct.2021.03.023</ArticleId><ArticleId IdType="pubmed">33775907</ArticleId></ArticleIdList></Reference><Reference><Citation>Burt R.K., Han X., Gozdziak P., Yaung K., Morgan A., Clendenan A.M., Henry J., Calvario M.A., Datta S.K., Helenowski I., et al. Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: Effect of conditioning regimen on outcome. Bone Marrow Transpl. 2018;53:692&#x2013;700. doi: 10.1038/s41409-018-0173-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41409-018-0173-x</ArticleId><ArticleId IdType="pubmed">29855561</ArticleId></ArticleIdList></Reference><Reference><Citation>Khorshid O., Hosing C., Bibawi S., Ueno N., Reveille J., Mayes M.D., Champlin R.E. Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus. J. Rheumatol. 2004;31:2513&#x2013;2516.</Citation><ArticleIdList><ArticleId IdType="pubmed">15570660</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Q., Lu L., Niu X., Guo Y., Parino G.R., Liu D. Non-myeloablative allogeneic stem cell transplant in a patient with refractory systemic lupus erythematosus. Bone Marrow Transpl. 2006;37:979&#x2013;981. doi: 10.1038/sj.bmt.1705359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bmt.1705359</ArticleId><ArticleId IdType="pubmed">16565734</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmont A.M., Bacigalupo A., Gualandi F., Bregante S., van Lint M.T., Geroldi S. Systemic lupus erythematosus complicated with thymoma and pure red cell aplasia (PCRA). CR of both complications following thymectomy and allogeneic haematopoietic SCT (HSCT), but persistence of antinuclear antibodies (ANA) Bone Marrow Transpl. 2014;49:982&#x2013;983. doi: 10.1038/bmt.2014.68.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2014.68</ArticleId><ArticleId IdType="pubmed">24820215</ArticleId></ArticleIdList></Reference><Reference><Citation>Greco R., Labopin M., Badoglio M., Veys P., Furtado Silva J.M., Abinun M., Gualandi F., Bornhauser M., Ciceri F., Saccardi R., et al. Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties. Front. Immunol. 2019;10:1570. doi: 10.3389/fimmu.2019.01570.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01570</ArticleId><ArticleId IdType="pmc">PMC6622152</ArticleId><ArticleId IdType="pubmed">31333680</ArticleId></ArticleIdList></Reference><Reference><Citation>Eshhar Z., Waks T., Gross G., Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA. 1993;90:720&#x2013;724. doi: 10.1073/pnas.90.2.720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.2.720</ArticleId><ArticleId IdType="pmc">PMC45737</ArticleId><ArticleId IdType="pubmed">8421711</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X., Chen X., Carpenter T.J., Wang J., Zhou R., Davis H.M., Heald D.L., Wang W. Development of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents. MAbs. 2018;10:876&#x2013;889. doi: 10.1080/19420862.2018.1480299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2018.1480299</ArticleId><ArticleId IdType="pmc">PMC6152432</ArticleId><ArticleId IdType="pubmed">29985776</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellebrecht C.T., Bhoj V.G., Nace A., Choi E.J., Mao X., Cho M.J., Di Zenzo G., Lanzavecchia A., Seykora J.T., Cotsarelis G., et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016;353:179&#x2013;184. doi: 10.1126/science.aaf6756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf6756</ArticleId><ArticleId IdType="pmc">PMC5343513</ArticleId><ArticleId IdType="pubmed">27365313</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadelain M., Riviere I., Riddell S. Therapeutic T cell engineering. Nature. 2017;545:423&#x2013;431. doi: 10.1038/nature22395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22395</ArticleId><ArticleId IdType="pmc">PMC5632949</ArticleId><ArticleId IdType="pubmed">28541315</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudecek M., Sommermeyer D., Kosasih P.L., Silva-Benedict A., Liu L., Rader C., Jensen M.C., Riddell S.R. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 2015;3:125&#x2013;135. doi: 10.1158/2326-6066.CIR-14-0127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-14-0127</ArticleId><ArticleId IdType="pmc">PMC4692801</ArticleId><ArticleId IdType="pubmed">25212991</ArticleId></ArticleIdList></Reference><Reference><Citation>Casucci M., Falcone L., Camisa B., Norelli M., Porcellini S., Stornaiuolo A., Ciceri F., Traversari C., Bordignon C., Bonini C., et al. Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene. Front. Immunol. 2018;9:507. doi: 10.3389/fimmu.2018.00507.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00507</ArticleId><ArticleId IdType="pmc">PMC5871667</ArticleId><ArticleId IdType="pubmed">29619024</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden P.J., Roddie C., Bader P., Basak G.W., Bonig H., Bonini C., Chabannon C., Ciceri F., Corbacioglu S., Ellard R., et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) Ann. Oncol. 2022;33:259&#x2013;275. doi: 10.1016/j.annonc.2021.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2021.12.003</ArticleId><ArticleId IdType="pubmed">34923107</ArticleId></ArticleIdList></Reference><Reference><Citation>Mougiakakos D., Kronke G., Volkl S., Kretschmann S., Aigner M., Kharboutli S., Boltz S., Manger B., Mackensen A., Schett G. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N. Engl. J. Med. 2021;385:567&#x2013;569. doi: 10.1056/NEJMc2107725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2107725</ArticleId><ArticleId IdType="pubmed">34347960</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackensen A., Muller F., Mougiakakos D., Boltz S., Wilhelm A., Aigner M., Volkl S., Simon D., Kleyer A., Munoz L., et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 2022;28:2124&#x2013;2132. doi: 10.1038/s41591-022-02017-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02017-5</ArticleId><ArticleId IdType="pubmed">36109639</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarczak D., Nierhaus A. Cytokine Storm-Definition, Causes, and Implications. Int. J. Mol. Sci. 2022;23:11740. doi: 10.3390/ijms231911740.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231911740</ArticleId><ArticleId IdType="pmc">PMC9570384</ArticleId><ArticleId IdType="pubmed">36233040</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira L.M.R., Muller Y.D., Bluestone J.A., Tang Q. Next-generation regulatory T cell therapy. Nat. Rev. Drug Discov. 2019;18:749&#x2013;769. doi: 10.1038/s41573-019-0041-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-019-0041-4</ArticleId><ArticleId IdType="pmc">PMC7773144</ArticleId><ArticleId IdType="pubmed">31541224</ArticleId></ArticleIdList></Reference><Reference><Citation>Raffin C., Vo L.T., Bluestone J.A. T(reg) cell-based therapies: Challenges and perspectives. Nat. Rev. Immunol. 2020;20:158&#x2013;172. doi: 10.1038/s41577-019-0232-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0232-6</ArticleId><ArticleId IdType="pmc">PMC7814338</ArticleId><ArticleId IdType="pubmed">31811270</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R., Werth V.P., Merola J.F., Stevenson L., Reynolds T.L., Naik H., Wang W., Christmann R., Gardet A., Pellerin A., et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J. Clin. Investig. 2019;129:1359&#x2013;1371. doi: 10.1172/JCI124466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI124466</ArticleId><ArticleId IdType="pmc">PMC6391094</ArticleId><ArticleId IdType="pubmed">30645203</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan X., Qin X., Wang D., Zhang Z., Tang X., Gao X., Chen W., Sun L. Mesenchymal stem cell therapy induces FLT3L and CD1c(+) dendritic cells in systemic lupus erythematosus patients. Nat. Commun. 2019;10:2498. doi: 10.1038/s41467-019-10491-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-10491-8</ArticleId><ArticleId IdType="pmc">PMC6555800</ArticleId><ArticleId IdType="pubmed">31175312</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight J.S., Subramanian V., O&#x2019;Dell A.A., Yalavarthi S., Zhao W., Smith C.K., Hodgin J.B., Thompson P.R., Kaplan M.J. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann. Rheum. Dis. 2015;74:2199&#x2013;2206. doi: 10.1136/annrheumdis-2014-205365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-205365</ArticleId><ArticleId IdType="pmc">PMC4320672</ArticleId><ArticleId IdType="pubmed">25104775</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok C.C. The Jakinibs in systemic lupus erythematosus: Progress and prospects. Expert Opin. Investig. Drugs. 2019;28:85&#x2013;92. doi: 10.1080/13543784.2019.1551358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13543784.2019.1551358</ArticleId><ArticleId IdType="pubmed">30462559</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson S., Thomas R. Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus. Front. Immunol. 2021;12:654701. doi: 10.3389/fimmu.2021.654701.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.654701</ArticleId><ArticleId IdType="pmc">PMC8322693</ArticleId><ArticleId IdType="pubmed">34335564</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>